Speaker: Dr. Yongfei Yang; 

VP, Antibody Research Institute at Biocytogen; 

Nanobodies are a novel class of therapeutic proteins. Significantly smaller than conventional antibodies, they consist only of the antigen-binding region of the heavy chain and offer unique advantages in drug discovery.

In this webinar, Dr. Yongfei Yang will delve into the exceptional properties of nanobodies, including how they retain the high specificity and affinity of traditional antibodies, maintain suitable stability, and facilitate the development of various drug modalities.

Key Topics Include:

• How Biocytogen’s proprietary RenNano discovery platform and Beacon high-throughput screening platform accelerate nanobody development.
• Case studies featuring TFR1, 4-1BB, and OX40 antibodies, highlighting their sequence diversity, optimal affinity, superb hydrophilicity, and favorable pharmacokinetic properties.
• The application prospects of fully human heavy chain-only antibodies (HCAbs) generated from RenNano mice in bispecific and multispecific antibodies, XDC, and cell therapies.
• Insights into Biocytogen’s "Nano 100 Project", aimed at large-scale nanobody discovery.